Alembic Pharma Share Price

Alembic Pharmaceuticals Limited, with its corporate operations in Vadodara, functions as a research-driven pharmaceutical manufacturing company in India. The company was incorporated in 1907 and began its operations as Alembic Chemical Works, making it one of India’s oldest pharmaceutical companies. Alembic Pharmaceuticals manufactures generic formulations, active pharmaceutical ingredients (APIs), and branded specialty products across various therapeutic segments including gastroenterology, ophthalmology, cardiology, nephrology, dermatology, oncology, and anti-infectives. The company operates its manufacturing facilities located in Gujarat and Sikkim and has a significant export presence, serving patients in over 90 countries across the globe.

Alembic share price today on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the pharmaceutical sector. The company’s financial health depends on API production volumes, raw material costs including chemical intermediates, capacity utilization rates across its three API plants in Gujarat and six formulation facilities, export demand from regulated markets such as the United States and Europe, and the performance of its international generics and branded specialty segments. Alembic stock price is influenced by various factors such as earnings, regulatory approvals from the USFDA, changes in drug pricing policies, and global generic API price trends. In the longer run, strategies such as expansion into complex generics, biosimilars, and specialty products, product portfolio diversification, and strengthening of the pipeline of abbreviated new drug applications (ANDAs) affect the stock market perceptions. All these factors need to be monitored closely to have an idea about the company’s stock price movements.

Alembic live share price provides real-time information about the last price traded, bid and ask prices, and trading volume. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Alembic live price helps in observing short-term price volatility and shows how a stock moves relative to the broader Nifty Pharma index. Furthermore, monitoring Alembic stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook.

Alembic Pharmaceuticals Limited Company Fundamentals

a. Company Background

Alembic Pharmaceuticals Limited was incorporated in 1907 and began its operations as Alembic Chemical Works. The company is engaged in the manufacturing and sale of pharmaceutical products, including generic formulations, APIs, and branded specialty medicines. The company operates primarily in the pharmaceutical segment, supplying products across various therapeutic categories including gastroenterology, ophthalmology, cardiology, nephrology, dermatology, oncology, and anti-infectives. Its manufacturing operations are based in India, with three API plants and six formulation manufacturing facilities located in Gujarat and Sikkim, while corporate functions are managed from its administrative office in Vadodara, Gujarat. Additionally, the company has research and development centers in Vadodara and Indore. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and international markets, with a strong focus on the United States. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in generic pharmaceuticals, regulatory approvals, and input cost fluctuations.

b. Company Product Lines

• Generic formulations include tablets, capsules, injectables, ophthalmics, and oral solids across various therapeutic categories for the regulated markets of the United States and Europe

• Branded specialty products include formulations marketed under the Alembic brand name in India and other emerging markets, focusing on high-growth therapeutic areas such as gastroenterology and ophthalmology

• Active Pharmaceutical Ingredients (APIs) include high-volume and specialty APIs manufactured at three dedicated plants, serving both internal formulation needs and external customers globally

• Complex generics include difficult-to-manufacture products such as ophthalmic solutions, injectables, and controlled-release formulations targeting niche generic opportunities

• Contract development and manufacturing services provide custom manufacturing of pharmaceutical products for global partners leveraging the company’s manufacturing capacity and regulatory approvals

The product portfolio is structured to serve both domestic and international markets across more than 90 countries.

c. Company Revenue Model

• Domestic branded formulation sales generate revenue through distribution of specialty pharmaceutical products to hospitals, clinics, and retail pharmacies across India under the Alembic brand name

• Export sales of generic formulations to the United States and Europe form the largest revenue segment, leveraging the company’s USFDA and EU GMP approved facilities

• API sales contribute revenue through supply of active pharmaceutical ingredients to domestic and international formulation manufacturers

• Contract manufacturing and institutional supply provide revenue through long-term agreements with global pharmaceutical partners

Revenue performance is primarily influenced by global demand for generic pharmaceuticals, raw material costs, regulatory approvals, and selling price realizations in export markets.

d. Geographic Presence

• Manufacturing facilities located in Gujarat (Karakhadi, Panelav, Jarod) and Sikkim (Rangpo)

• Corporate office situated in Vadodara, Gujarat

• Domestic distribution network serves customers across India through direct supply channels to hospitals, clinics, and retail pharmacies

• Export markets include the United States, Europe, Canada, Australia, South Africa, Brazil, Russia, and over 90 countries worldwide

e. Key Milestones

• 1907: Founding of the company as Alembic Chemical Works

• 1960s-1980s: Expansion of manufacturing capabilities and entry into new therapeutic segments

• 2000s: Focus on international generics market and establishment of USFDA compliant facilities

• 2010: Conversion of the company into a public limited entity

• 2010: Initial Public Offering (IPO) launched and listed on stock exchanges

• 2025: The company continued to file ANDAs with the USFDA and received multiple final approvals, impacting the product pipeline

• 2026: Received 5 ANDA approvals in a month, strengthening the US generics portfolio

• Recent years: Continued focus on complex generics, biosimilars, specialty products, and cost optimization initiatives

f. Industry Perspective

The pharmaceutical API and formulation manufacturing industry is research-intensive and closely linked to demand from global generic drug manufacturers, healthcare providers, and distribution channels. Demand trends are influenced by patent expirations of blockbuster drugs, the growth of generic pharmaceutical markets, increasing healthcare access, and population demographics.

The industry is also affected by fluctuations in raw material prices such as chemical intermediates and solvents, along with energy and logistics costs. Regulatory compliance with quality standards from agencies like USFDA, WHO-GMP, and European authorities increasingly shapes production practices and capital investment decisions. Pricing pressure from US generic buyers and changes in US healthcare policies remain key challenges.

Companies in the sector must manage patent expirations, intense global competition from Chinese and Indian API manufacturers, pricing pressure from buyers, and regulatory compliance while maintaining operational efficiency. These factors collectively influence financial performance and investor perception of firms like Alembic Pharmaceuticals.

Alembic Pharmaceuticals Limited Stock Market Presence: Listings & Index Representation

Alembic Pharmaceuticals Limited is listed on the National Stock Exchange (NSE) under the symbol APLLTD and on the Bombay Stock Exchange (BSE) with the scrip code 533573. Alembic share price is actively traded on both exchanges. The company’s market presence is within the mid-cap segment of the market. Due to its size and sector focus, Alembic stock price is generally tracked by investors interested in the API and generic pharmaceutical manufacturing industry.

Alembic Pharmaceuticals Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a mid-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the Nifty Midcap 100 and Nifty Pharma indices. Alembic share price finds representation in these indices based on its market standing. Alembic stock price presence in these indices helps investors track the company relative to other API and generic pharmaceutical manufacturing companies.

Alembic Pharmaceuticals Limited Stock Performance and Share Price History

Alembic share price on the NSE reflects its position as a vertically integrated generic pharmaceutical manufacturer with a strong focus on the US generics market. Its performance is qualitatively driven by factors such as production capacity utilization across its API and formulation facilities, management of raw material costs including chemical intermediates, growth in ANDA filings and approvals from the USFDA, and the ability to maintain regulatory compliance. Investors compare the Alembic share price movement with other pharmaceutical companies to assess relative strength.

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported Alembic share price. Beyond operational and sector influences, corporate actions such as the company’s high number of ANDA filings, receipt of final approvals, and launch of new generic products in the United States can significantly affect share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by USFDA inspections, drug pricing policies, and global API demand cycles.

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by the stock’s annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger export demand and stable raw material margins, whereas a significant low aligns with market corrections or sector volatility. Alembic share price extremes reflect the impact of regulatory actions, global pharmaceutical pricing trends, and earnings visibility, providing a framework for understanding historical performance.

Alembic stock price behaviour mirrors the trading patterns of a mid-cap pharmaceutical company within India’s generics manufacturing ecosystem. The company’s diversified portfolio spanning APIs, generic formulations, and branded products has shaped its price history. Over recent years, Alembic share price has experienced periods of sharp gains driven by USFDA approvals and strong export orders, followed by phases of consolidation amid pricing pressures in the US market and raw material cost inflation. The stock has shown a certain level of volatility compared to the broader market, aligning with the cyclical nature of the generics industry.

The company’s performance has closely tracked global generic drug demand, USFDA approval cycles, and raw material cost trends. Positive momentum appeared during periods of increased product approvals and launches in the US market, which boosted export revenues. However, periods of pricing pressure from US generic buyers, intense competition from Chinese API manufacturers, and elevated raw material costs have led to consolidation in Alembic share price. Profitability has shown patterns aligned with the company’s ability to manage input costs and the timing of new product launches.

Despite global supply chain disruptions, Alembic shares showed resilience during challenging periods. While the broader pharmaceutical sector faced headwinds from input cost inflation, the company’s diversified product portfolio and multiple manufacturing locations helped Alembic share price navigate industry cycles. The company maintains a significant workforce and exports to over 90 countries worldwide. It has also continued to file ANDAs with the USFDA, maintaining a healthy pipeline.

Alembic share price has declined for several recurring reasons. A drop in global generic drug demand or pricing pressure from US buyers directly impacts profitability and leads to selling pressure. Changes in government policy regarding API import restrictions or manufacturing quality standards can also cause Alembic share price to fall. Moreover, increases in operational costs without matching price increases compress margins, making the stock less attractive. Periods of global economic slowdown that affect pharmaceutical spending raise concerns about export order volumes, leading to price declines. The stock is sensitive to raw material price movements; if chemical intermediate costs rise significantly, it can cause Alembic share price to fall as investors adjust expectations for future margin growth. Broader market sell-offs in mid-cap stocks also pull Alembic share price down, regardless of the company’s individual performance. Delays in regulatory approvals for new product registrations or warning letters from the USFDA can also weigh on investor sentiment, resulting in lower valuation.

Alembic Pharmaceuticals Limited Investor Relevance and Role in Portfolio

Alembic Pharmaceuticals Limited is a holding in mid-cap and pharmaceutical sector portfolios, offering exposure to generic formulations, APIs, and branded specialty products with a strong focus on the US generics market. Its inclusion in pharma indices underscores its importance in India’s generic pharmaceutical manufacturing space. The company’s position as a vertically integrated manufacturer with a strong pipeline of ANDA filings, together with its multiple manufacturing facilities and export reach to over 90 countries, makes it a consideration for long-term allocations.

Alembic share price receives influence from the company’s ownership structure. Alembic Pharmaceuticals equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of around 67 percent of the company’s total shares, reflecting strong internal control. Foreign institutional investors hold a notable portion of the company’s shares, with holdings around 20 to 25 percent. Domestic institutional investors maintain a modest holding. Mutual funds also hold a stake. The public holds the remaining share. The company’s management includes members of the Patel family, the founding promoters. This investor base, with stable promoter participation and significant institutional ownership, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on API and generic pharmaceutical manufacturing.

Beyond fundamentals and ownership, the stock is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on raw material prices, export orders for generics, and regulatory policy actions from the USFDA. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in US drug pricing policies or import alerts.

Technical indicators provide additional insight into short-term momentum shifts in Alembic stock price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, the stock’s beta indicates a certain level of volatility compared to the broader market. The company’s debt to equity ratio reflects a moderate use of leverage. Return on equity and return on capital employed are at certain levels, and the company’s book value per share is a reference point for valuation.

Overall, Alembic Pharmaceuticals demonstrates a certain volatility profile compared to the broader market, with the stock generally considered to have moderate systematic risk. This makes it responsive to broader market movements and sector-specific factors such as raw material price fluctuations, regulatory approvals, and global generic drug demand cycles.

Alembic Pharmaceuticals Limited Sectoral Relevance and Peer Positioning

Alembic Pharmaceuticals Limited sector relevance stems from its over century-long presence in the pharmaceutical industry since 1907, its position as a vertically integrated manufacturer of APIs, generics, and branded specialty products, its portfolio spanning gastroenterology, ophthalmology, cardiology, nephrology, dermatology, oncology, and anti-infectives, its manufacturing facilities located across Gujarat and Sikkim with three API plants and six formulation facilities, its strong focus on the US generics market with a pipeline of ANDA filings, its approvals from USFDA and other global regulators, and its export presence to over 90 countries including the United States, Europe, Canada, Australia, and South Africa, establishing it as a focused mid-cap pharmaceutical provider supporting India’s generic drug export ecosystem. Peer comparisons with companies like Torrent Pharmaceuticals, Cadila Healthcare, and other API-focused pharmaceutical companies focus on regulatory certifications, ANDA pipeline, export intensity, and value-added formulation diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API molecule pricing, global generic drug demand trends, and government pharmaceutical manufacturing policies further highlights Alembic Pharmaceuticals positioning within India’s broader generic pharmaceutical manufacturing market.

Alembic market cap highlights its position as a mid-cap player within India’s pharmaceutical sector. Based on recent data, the company’s market capitalization fluctuates within a range depending on the reporting period. The market cap has moved in line with investor perceptions of the company’s growth potential following its ANDA filings and approvals. From earlier years through more recent periods, Alembic market cap showed an increasing trend as the company expanded its manufacturing capacity and diversified its product portfolio, followed by phases of consolidation due to pricing pressures and competitive intensity. This pattern reflects investor confidence during favourable generic drug cycles with strong demand for affordable medicines, followed by contraction during challenging periods impacted by intense competition and rising input costs. This decrease mirrors the correction in the share price from its annual high to recent levels.

Alembic earnings trajectory demonstrates the impact of its operational execution in a competitive global generic industry. In recent fiscal years, total income showed trends supported by the core API and generic formulation business. Based on available data, the company’s revenue from operations increased from previous fiscal periods to more recent periods, supported by strong export demand. However, profit after tax has shown variability, impacted by raw material cost inflation and pricing pressures in the US market. The company continued to file ANDAs with the USFDA and received multiple final approvals in a recent month, strengthening its product pipeline. Alembic earnings have faced headwinds from fluctuating raw material costs, competitive pressures from international generic producers, and pricing pressure from buyers, especially in the US market. However, the company has expanded its product portfolio and focused on complex generics to strengthen its market position, and expects growth from new product launches.

Alembic EPS provides insight into its operational performance and income generation from API sales, generic formulations, and branded products. The company reported certain levels of basic EPS in recent quarters that showed movement compared to previous quarters and corresponding quarters of prior years, reflecting the impact of margin pressures. The trailing twelve-month EPS stands at certain levels depending on the reporting period. Alembic EPS for recent full fiscal years showed patterns compared to prior fiscal years, reflecting the impact of demand cycles, regulatory approvals, and cost structures.

Alembic P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from API sales, generic formulations, and branded specialty products. Based on available data, the current P/E ratio stands at a certain level compared to the industry average. The company’s profit after tax has shown patterns from previous fiscal years to the most recent fiscal year. Quarterly performance has demonstrated mixed movement, with profit after tax showing variability from earlier quarters to later quarters, accompanied by movement in total income on a quarter-on-quarter basis. Alembic P/E ratio reflects how market sentiment evolves alongside the company’s operational performance in a competitive global industry.

Summary

Alembic Pharmaceuticals Limited operates as a mid-cap vertically integrated generic pharmaceutical manufacturer with a history spanning over a century. Alembic share price gets influenced by global demand for generic drugs, raw material costs, regulatory approvals from the USFDA, and the company’s ability to file and launch new products in the US market. The company’s strong presence in the API and generic formulation segments, its multiple manufacturing facilities, and its robust ANDA pipeline support its market position. Alembic stock price reflects operational execution within the competitive generic pharmaceutical sector. The ownership structure shows stable promoter holding of around 67 percent with significant institutional participation and a retail minority.